A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and Gastroesophageal Junction Cancers

Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06243757

Enrollment

Registered

2024-02-06

Start date

2024-01-08

Completion date

2036-01-08

Last updated

2026-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer, GastroEsophageal Cancer, Gastroesophageal Junction Adenocarcinoma

Keywords

gastric cancer, non-metastatic gastric cancer, Gastroesophageal Junction Adenocarcinoma, gastroesophageal cancer, GEJ adenocarcinoma, MIPG, MITG, Minimally Invasive Proximal Gastrectomy, Minimally Invasive total gastrectomy, 23-324, Memorial Sloan Kettering Cancer Center

Brief summary

Participants will a diagnosis of gastroesophageal junction (GEJ) adenocarcinoma and will have either a minimally invasive proximal gastrectomy (MIPG) or a minimally invasive total gastrectomy (MITG) as part of their routine care. Participants with complete a questionnaire 1 month before the surgical procedure and then 1, 3, 6 and 12 months after the surgical procedure.

Interventions

OTHERMDASI-GI

The MDASI-GI assesses 5 symptoms specific to gastrointestinal cancer: constipation diarrhea or watery stools difficulty swallowing change in taste feeling bloated Using this questionnaire, participants score the severity of their symptoms over the previous 24 hours on a scale of 0 (not present) to 10 (as bad as you can imagine).

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Able to speak and read English, Spanish, Japanese or Korean * Patients with a biopsy-confirmed diagnosis of non-metastatic gastric or GEJ adenocarcinoma, who are scheduled to undergo MIPG or MITG for curative-intention * Age ≥ 18

Exclusion criteria

* Patients with known malabsorption syndromes or a lack of physical integrity of the upper gastrointestinal tract * Patients with known narcotic dependence, with average daily dose \> 5 mg oral morphine equivalent * Subjects deemed unable to comply with study and/or follow-up procedures, at investigators' discretion * Patients who are pregnant (since are excluded from receiving standard-of-care MIPG or MITG)

Design outcomes

Primary

Measure	Time frame	Description
Appetite level score according to the MDASI-GI	3 months after surgery	The primary outcome is the appetite level score (with 0 being the best and 10 being the worst) according to the MDASi-GI at 3 months after surgery

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORVivian Strong, MD

Memorial Sloan Kettering Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 23, 2026